STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

ALISO VIEJO, Calif. & BALTIMORE--(BUSINESS WIRE)--Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces specific results from one of three ...

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GeneDx (Nasdaq: WGS), a ...

We evaluated the feasibility of high-resolution noninvasive prenatal screening in 51 pregnancies that were representative of the pregnant population receiving care at the recruitment hospital (Tables ...

GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% year-over-year increase and within its previously raised guidance range of $425 ...